Valtecne (VLT) Q4 2024 TU earnings summary

Executive summary

• FY 2024 sales reached €30.4 million, slightly down 1.1% year-over-year from €30.7 million in 2023.

• Medical business line exceeded €20 million in revenue for the first time, growing 15.1% year-over-year to €21.3 million.

• Industrial business line declined 25.4% year-over-year to €9.1 million due to ongoing weakness in European manufacturing.

• Strategic focus continues to shift toward the med-tech and orthopedic sectors, supported by recent M&A activity.

Segment performance

• Medical segment accounted for 69.9% of total revenue in 2024, up from 60.1% in 2023.

• Industrial segment represented 30.1% of total revenue, down from 39.9% in 2023.

Significant events and developments

• Acquired 60% of Utilità S.r.l., a precision contract manufacturer for dental and orthopedic medical components; closing expected in Q1 2025.

• This marks the first M&A transaction in company history, aimed at strengthening strategic positioning and accelerating growth.